The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. Knaus WA, Harrell FE, Fisher CJ, Wagner DP, Opal SM, Sadoff JC, Draper EA, Walawander CA, Conboy K, Grasela TH (1993) JAMA 270: 1233-41 American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE (2014) J Clin Oncol 32: 1277-80 Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK (2011) J Clin Oncol 29: 3450-6 Gastrointestinal carcinoma antigen GA733: target for immunodestruction and potential modifier of invasiveness and chemoresponsiveness. Zutter MM (1998) J Natl Cancer Inst 90: 642-4 Aflibercept. Ciombor KK, Berlin J, Chan E (2013) Clin Cancer Res 19: 1920-5 Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Bernard GR (2003) Crit Care Med 31: S85-93 Targeting angiogenesis in advanced non-small cell lung cancer. Lammers PE, Horn L (2013) J Natl Compr Canc Netw 11: 1235-47 A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG (2017) Br J Haematol 178: 547-560 Common genetic variants in the vitamin D pathway including genome-wide associated variants are not associated with breast cancer risk among Chinese women. Dorjgochoo T, Delahanty R, Lu W, Long J, Cai Q, Zheng Y, Gu K, Gao YT, Zheng W, Shu XO (2011) Cancer Epidemiol Biomarkers Prev 20: 2313-6 EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. Chmielecki J, Pietanza MC, Aftab D, Shen R, Zhao Z, Chen X, Hutchinson K, Viale A, Kris MG, Stout T, Miller V, Rizvi N, Pao W (2012) J Thorac Oncol 7: 434-42 Calcium/magnesium intake ratio, but not magnesium intake, interacts with genetic polymorphism in relation to colorectal neoplasia in a two-phase study. Zhu X, Shrubsole MJ, Ness RM, Hibler EA, Cai Q, Long J, Chen Z, Li G, Jiang M, Hou L, Kabagambe EK, Zhang B, Smalley WE, Edwards TL, Giovannucci EL, Zheng W, Dai Q (2016) Mol Carcinog 55: 1449-57 Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity. Moore MC (2006) Curr Opin Investig Drugs 7: 924-35 Targeting vascular endothelial growth factor in colorectal cancer. Berlin JD (2002) Oncology (Williston Park) 16: 13-5 Second-line therapy in colorectal cancer. Berlin J (2000) Oncology (Williston Park) 14: 21-6 Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. Solomon SB, Zakowski MF, Pao W, Thornton RH, Ladanyi M, Kris MG, Rusch VW, Rizvi NA (2010) AJR Am J Roentgenol 194: 266-9 Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks. Godfrey CC, Michelow PM, Godard M, Sahasrabuddhe VV, Darden J, Firnhaber CS, Wetherall NT, Bremer J, Coombs RW, Wilkin T, A5282 Study Team (2013) Am J Clin Pathol 140: 881-9 Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Johnson DB, Puzanov I, Kelley MC (2015) Immunotherapy 7: 611-9 Renal cell therapy in the treatment of patients with acute and chronic renal failure. Humes HD, Weitzel WF, Fissell WH (2004) Blood Purif 22: 60-72 Proper inference from Simon's two-stage designs. Koyama T, Chen H (2008) Stat Med 27: 3145-54 Analysis of longitudinal laboratory data in the presence of common selection mechanisms: a view toward greater emphasis on pre-marketing pharmaceutical safety. Schildcrout JS, Jenkins CA, Ostroff JH, Gillen DL, Harrell FE, Trost DC (2008) Stat Med 27: 2248-66 Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG (2008) Clin Colorectal Cancer 7: 184-90
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.